On August 7, Novo-Nordisk A/S rose 3.09% in pre-market trading, trading at $47.39/share, with turnover of $2.3258 million, extending its multi-day rebound driven by strong Q2 results and a favorable patent ruling.

On the news front, the company reported Q2 adjusted EPS of $0.96, beating the consensus estimate of $0.81 by 18.5%, while sales of $12.209 billion also surpassed the $11.35 billion estimate. The company simultaneously raised full-year sales and operating profit guidance, primarily driven by elevated GLP-1 product sales expectations. Additionally, the District Court of The Hague issued a preliminary injunction ordering Ceban Ziekenhuisfarmacie B.V. to immediately stop selling its compounded semaglutide nasal spray, ruling it infringed Novo Nordisk's supplementary protection certificate. BMO also raised its target price from $45 to $47.

The stock had previously plunged nearly 10% after its cardiac drug ziltivekimab failed a Phase 3 trial in late July. The ongoing recovery reflects market repricing of core GLP-1 business resilience and strengthened intellectual property protection.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)